97P Cost-effectiveness of TTFields in addition to standard systemic therapy for stage IV non-small cell lung cancer patients following progression on or after platinum-based chemotherapy

Tumor Treating Fields (TTFields) + standard therapy (investigator's choice of docetaxel or immune checkpoint inhibitor [ICI]) significantly prolonged overall survival compared to standard therapy alone in patients with stage IV non-small cell lung cancer (NSCLC) following progression on or after platinum-based therapy. This study aims to estimate the cost-effectiveness of adding TTFields to standard therapy. A three-state (stable disease, progressive disease, and death) partitioned survival model was developed from a US payer perspective over a lifetime time horizon. Results from the phase III randomized LUNAR study (TTFields + standard therapy compared to standard therapy alone) were used to estimate long-term overall survival and progression-free survival using parametric extrapolation. A subgroup analysis examined TTFields with docetaxel and an ICI separately. Previously published utilities were used to calculate quality-adjusted life-years (QALYs). Treatment, administration, monitoring, and adverse event costs were sourced from the published fee schedules and MediSpan. Costs and benefits were discounted at 3% per year. Patients treated with TTFields + standard therapy had a mean lifetime survival of 2.44 years (2.17 discounted) compared to 1.31 (1.26 discounted) for standard therapy-alone. QALYs were 1.78 (1.58 discounted) for TTFields + standard therapy compared to 0.97 (0.93 discounted) for standard therapy-alone. Incremental total costs were $59,217 ($58,505 discounted) higher for TTFields + standard therapy. The incremental cost-effectiveness ratio (ICER) was $89,012 per QALY gained and $64,316 per life-year gained. This analysis revealed that TTFields + standard therapy is cost-effective compared to standard therapy alone in patients with stage IV NSCLC after platinum-based chemotherapy.Table: 97PCost-effectiveness resultsTTFields + standard therapyStandard therapyDifferenceDiscounted costsTreatment$68,431$13,986$54,445Administration$424$327$97 Supportive care$5,039$2,922$2,117Adverse events$3,511$1,665$1,846Total$77,406$18,901$58,505Discounted OutcomesLife-Years2.171.260.91QALYs1.580.930.66ICER (QALYs)$89,012 Open table in a new tab